@article{bdd27258bfb84412b986baab7b2f1340,
title = "Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has dramatically altered the landscape for testing new drugs for IPF treatment. These drugs slowed the progression of the FVC decline observed in IPF cohorts in phase III randomized, double-blind, placebo-controlled trials (3, 4).",
keywords = "Anti-Inflammatory Agents, Non-Steroidal, Clinical Trials as Topic, Drug Approval, Drug Development, Drug Interactions, Drug Therapy, Combination, Humans, Idiopathic Pulmonary Fibrosis, Indoles, Patient Outcome Assessment, Protein Kinase Inhibitors, Pyridones, Quality of Life, Standard of Care, Vital Capacity, Walk Test, Anti-Inflammatory Agents, Non-Steroidal, Clinical Trials as Topic, Drug Approval, Drug Development, Drug Interactions, Drug Therapy, Combination, Humans, Idiopathic Pulmonary Fibrosis, Indoles, Patient Outcome Assessment, Protein Kinase Inhibitors, Pyridones, Quality of Life, Standard of Care, Vital Capacity, Walk Test",
author = "Kaner, {Robert J.} and Bajwa, {Ednan K.} and Moustapha El-Amine and Eduard Gorina and Renu Gupta and Lazarus, {Howard M.} and Luckhardt, {Tracy R.} and Majd Mouded and Kaity Posada and Luca Richeldi and John Stauffer and Ahmet Tutuncu and Martinez, {Fernando J.}",
year = "2019",
doi = "10.1164/rccm.201903-0592PP",
language = "English",
volume = "200",
pages = "133--139",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Lung Association:61 Broadway:New York, NY 10006:(212)315-8625, INTERNET: http://www.thoracic.org, Fax: (212)315-8613",
}